About Apnimed
Apnimed is a company based in Cambridge (United States) founded in 2017 by Lawrence G Miller.. Apnimed has raised $224.33 million across 7 funding rounds from investors including NexPoint, Alpha Wave Global and Sectoral Asset Management. Apnimed offers products and services including AD109. Apnimed operates in a competitive market with competitors including Aculys, Avadel Pharmaceuticals, Mosanna Therapeutics, Circadian Therapeutics and sofi, among others.
- Headquarter Cambridge, United States
- Founders Lawrence G Miller
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Apnimed Inc
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$224.33 M (USD)
in 7 rounds
-
Latest Funding Round
$23 M (USD), Debt – Conventional
Sep 17, 2025
-
Investors
NexPoint
& 6 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Apnimed
Apnimed offers a comprehensive portfolio of products and services, including AD109. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Investigational treatment for improving oxygenation in obstructive sleep apnea.
Unlock access to complete
Funding Insights of Apnimed
Apnimed has successfully raised a total of $224.33M across 7 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $23 million completed in September 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 7
- Last Round Debt – Conventional — $23.0M
-
First Round
First Round
(07 Aug 2019)
- Investors Count 7
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2025 | Amount | Debt – Conventional - Apnimed | Valuation |
investors |
|
| Apr, 2025 | Amount | Series C - Apnimed | Valuation |
investors |
|
| Dec, 2022 | Amount | Series C - Apnimed | Valuation | Alpha Wave Global |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Apnimed
Apnimed has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include NexPoint, Alpha Wave Global and Sectoral Asset Management. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on growth-stage companies
|
Founded Year | Domain | Location | |
|
Sectoral Asset Management is focused on global healthcare investment.
|
Founded Year | Domain | Location | |
|
Venture capital firm focused on multiple sectors
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Apnimed
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Apnimed
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Apnimed Comparisons
Competitors of Apnimed
Apnimed operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Aculys, Avadel Pharmaceuticals, Mosanna Therapeutics, Circadian Therapeutics and sofi, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutic medicines for neuropsychiatric and sleep disorders are developed.
|
|
| domain | founded_year | HQ Location |
Proprietary drug delivery technologies and narcolepsy treatments are developed.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for sleep apnea are developed.
|
|
| domain | founded_year | HQ Location |
Developer of therapeutics to treat circadian rhythm disruption
|
|
| domain | founded_year | HQ Location |
Provider of natural remedy based mental & physical wellbeing services
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Apnimed
Frequently Asked Questions about Apnimed
When was Apnimed founded?
Apnimed was founded in 2017 and raised its 1st funding round 2 years after it was founded.
Where is Apnimed located?
Apnimed is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Who is the current CEO of Apnimed?
Lawrence G Miller is the current CEO of Apnimed. They have also founded this company.
Is Apnimed a funded company?
Apnimed is a funded company, having raised a total of $224.33M across 7 funding rounds to date. The company's 1st funding round was a Series C of $79.75M, raised on Aug 07, 2019.
What does Apnimed do?
Apnimed was founded in 2017 and is based in Cambridge, United States. Small molecule-based therapeutics are developed by the company within the biotechnology sector for treating obstructive sleep apnea. A combination therapy of atomoxetine and oxybutynin has been formulated to lessen the conditions severity. Neurological mechanisms controlling upper airway dilator muscles are addressed, resulting in enhanced respiration and oxygenation while sleeping. Operations focus on advancing these treatments through clinical development.
Who are the top competitors of Apnimed?
Apnimed's top competitors include Mosanna Therapeutics, Avadel Pharmaceuticals and Aculys.
What products or services does Apnimed offer?
Apnimed offers AD109.
Who are Apnimed's investors?
Apnimed has 7 investors. Key investors include NexPoint, Alpha Wave Global, Sectoral Asset Management, Tao Capital Partners, and Columbia-Seligman Investments.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.